InsidersTradesSigma
Follow the 에임드바이오 stock price and the full insider trade history of the company, a listed equity based in South Korea. Shares trade on the KR market, under the oversight of DART (FSS). Operating in the Health Care sector, 에임드바이오 has published 3 reports. Market capitalisation: €1,552.6bn. The latest transaction was filed on 17 March 2026 (Sale). Among the most active insiders: 인터베스트. The full history is openly available.
3
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
€69m
2 ops.
Sell Volume
10Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 17 March 2026
关于 에임드바이오
AimdBio 是一家在 XKRX 市场上市的健康和制药公司。它专注于开发创新的生物制药解决方案。